Comparing the current results to its competitors, Molecular Partners Ag reported Revenue decrease in the 4 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 17.93 %, recorded in the same quarter.
Molecular Partners Ag, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 24.94 %
Molecular Partners Ag's Comment on Competition and Industry Peers
The company operates in a competitive environment for drug discovery and development, facing competition from established pharmaceutical companies, biotechnology firms, universities, and other research or commercial institutions. Many competitors possess greater financial, research, and development resources. Large pharmaceutical companies have extensive experience in clinical testing, regulatory approvals, patient recruitment, and manufacturing pharmaceutical products. Smaller and early-stage companies also represent competition. Additionally, the expiration of base patents related to DARPin technology may enable competitors to utilize the technology, which could impact the company's competitive position.
November 3, 2025
Breakthrough and Challenges: Molecular Partners Unveils Pioneering Preclinical Data Amidst Financial Hurdles ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. November 3, 2025 In an exciting development for the field of cancer immunotherapy, Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotechnology powerhouse, has presented further preclinical proof-of-concept data that underscores its innovative approach with logic-gated CD3 Switch-DARPin T cell engager (TCE). This sophisticated therapeutic candidate integrates CD2 co-stimulation, marking a potential leap forward in cancer treatment strategies. The announcement took center stage at the Society for Immunotherapy of Cancer (SITC) 20...
August 26, 2024
Molecular Partners AG, a leading clinical-stage biotech company based in Zurich-Schlieren, Switzerland, continues to break new ground in the field of protein therapeutics through its innovative platform utilizing Designed Ankyrin Repeat Proteins (DARPin). In an invigorating announcement on June 11, 2024, the company outlined its corporate highlights for the first half of 2024, particularly focusing on the nomination of its first Radio-DARPin Therapy (RDT) candidate, MP0712. This announcement coincides with their fruitful partnership with Orano Med, a company specializing in radiopharmaceuticals, which has collectively contributed to the exciting advancements in targeted cancer therapies. The Launch of MP071...
June 14, 2024
Molecular Partners Presents Promising Data on DARPin Therapeutics Across Multiple Fronts at International Conferences and Publications ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 1-14, 2024 - Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company at the forefront of developing DARPin therapeutics, has recently unveiled significant advances in its multifaceted research pipeline. These revelations were made through presentations at prestigious conferences and in peer-reviewed publications, marking substantial progress in their endeavor to introduce custom-built protein drugs to address unmet medical needs. MP0621: A Milestone in Hematopoietic Stem Cell Transplantation (HSC...
June 11, 2024
Molecular Partners and Orano Med Report Promising Preclinical Data on Novel Radiopharmaceuticals June 11, 2024 - Zurich-Schlieren, Switzerland, Concord, Mass., and Paris - Molecular Partners(https://www.globenewswire.com/Tracker data=OSD7vmGVEbVAsNMV8hJaq5rF979qq-i44SjCLAgsgvV9t9xM73YqViqymzpbaIwFvEzkoIpiKNXVZ77CNXKcEyI6yJB4QvupNxUtvSgC0b0=) AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotechnology company specializing in DARPin (Designed Ankyrin Repeat Proteins) therapeutics, along with Orano Med, a clinical-stage radiopharmaceutical entity focusing on targeted alpha therapies utilizing lead-212 (^212Pb), has announced encouraging preclinical data for their DLL3-targeting Radio-DARPin therapy (RDT) can...
January 5, 2024
Molecular Partners and Orano Med Team Up to Develop Cutting-Edge Radio-DARPin Therapies to Combat CancerZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., and PARIS, Jan. 05, 2024 - In a significant move towards innovative cancer treatments, Molecular Partners AG and Orano Med have announced a strategic collaboration to co-develop Radio-DARPin therapeutics (RDTs). Molecular Partners, a clinical-stage biotech company known for its DARPin therapeutics, and Orano Med, a leading expert in targeted alpha therapy, aim to utilize Orano Med s 212Pb radioisotope as a payload to selectively eliminate cancer cells. Focused on advancing multiple oncology targets, with DLL3 being the first target, both parties have commit...
Coherus Biosciences Inc is a biopharmaceutical company focused on developing and commercializing high-quality biosimilar therapeutics. Their business model revolves around leveraging their expertise in cell culture, protein purification, formulation development, and analytical methods to manufacture and market biosimilar products. By providing cost-effective alternatives to expensive biologic drugs, Coherus Biosciences aims to make healthcare more accessible and affordable for patients.
Calidi Biotherapeutics Inc's business model revolves around developing and commercializing innovative cell-based immunotherapies for the treatment of cancer.
Compass Therapeutics Inc operates as a biotechnology company focused on discovering and developing novel antibody therapeutics for the treatment of cancer and autoimmune diseases. Their business model revolves around leveraging their proprietary Targeted Immunomodulation platform to identify and advance multiple antibody candidates through preclinical and clinical development stages.
Cardiol Therapeutics Inc. operates on a business model focused on the research and development of pharmaceutical-grade cannabidiol (CBD) and targeted therapies for cardiovascular diseases. The company aims to leverage its expertise to develop innovative and effective treatments to address unmet medical needs in the field of heart-related conditions.
Elevai Labs Inc operates on a subscription-based model, providing users with access to their proprietary software platform that utilizes artificial intelligence technology. The platform is designed to assist businesses in automating mundane and repetitive tasks, improving operational efficiency. Elevai Labs generates revenue through monthly or annual fees charged to their customers based on the level of usage.
Sources:
Molecular Partners Ag’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Molecular Partners Ag versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
